NVIV
$1.01
Invivo Therapeutics Holdings
($.10)
(9.01%)
NVIV
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Thursday
Nov 5
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when NVIV reports earnings?
Beat
Meet
Miss

Where is NVIV's stock price going from here?
Up
Flat
Down
Stock chart of NVIV
Analysts
Summary of analysts' recommendations for NVIV
Score
Grade
Pivots
Resistance
$1.16
$1.10
$1.06

$1.00

Support
$0.95
$0.89
$0.84
Tweet
Growth
Description
InVivo Therapeutics Holdings Corp. operates as a medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company intends to offer three products, including a biocompatible polymer scaffolding device to treat acute wound SCI; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute SCI; and a biocompatible polymer scaffolding device seeded with autologous hNSCs to treat acute and chronic SCI. InVivo Therapeutics Holdings Corp. is based in Cambridge, Massachusetts.
Peers
Boston ScientificStrykerBecton, DickinsonBaxter InternationalAbbottWatersIntegra LifeSciences HoldingsCardiovascular SystemsHill-Rom Holdings3M